Ideal for: KRAS, epithelial-to-mesenchymal transition (EMT), circulating tumor markers, radiolabeled nucleotide therapy

MIA Paca-2 is a hypotriploid human pancreatic cancer cell line widely used to study pancreatic ductal adenocarcinoma carcinogenesis. MIA Paca-2 cells are KRAS mutant, have a p53 mutation, contain a p16 (CDKN2A) homozygous deletion and are wild type for Smad41,2.

MIA Paca-2 cells are epithelial as they express CK5.6, AE1/AE3, and E-cadherin1,2. They also have characteristics of a mesenchymal phenotype with vimentin expression2. This has allowed MIA Paca-2 cells to be characterized as epithelial-mesenchymal which makes them an important intermediate model of the epithelial-to-mesenchymal transition (EMT). EMT is the process that initiates metastasis by switching epithelial tumor cells to the mesenchymal phenotype required to leave the parent tumor and ultimately colonize in distant tissues3,4. Targeting EMT and preventing metastasis has been a hot-button issue in cancer pharmacology for decades and one of the greatest limitations to studying this phenomenon has been the ability to replicate the EMT process in an in vivo model4,5. The reliable growth kinetics of MIA Paca-2 cells in the OncoRat are poised to make in vivo EMT research possible in the most physiologically relevant way available.

MIA Paca-2 cells demonstrate neuroendocrine differentiation with chromogranin A and synaptophysin expression2. Additionally, they express the hormone receptors SSTR2 and NTR1 that may enable the testing of peptide receptor radiolabeled nucleotide therapy in this cell line2

Request A Proposal
Download Publications

Enabling Case Study: MIA Paca-2 tumor kinetics in the OncoRat

OncoRat MIA Paca-2 products & services

  • Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
  • OncoRats off-the-shelf for engraftment at the customers facility
  1. Deer EL, González-Hernández J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39(4):425-435.
  2. Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A. MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Scientific reports. 2016;6:21648.
  3. Gupta S, Maitra A. EMT: Matter of Life or Death? Cell. 164(5):840-842.
  4. Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6(13):10697-10711.
  5. Ombrato L, Malanchi I. The EMT universe: space between cancer cell dissemination and metastasis initiation. Critical reviews in oncogenesis. 2014;19(5):349-361.